Our findings confirm associations of TP53 loss with worse human patient PDAC outcomes and with increased tumor growth and gemcitabine resistance in mouse models [73–76], although one clinical trial of PDAC patients reported an opposite effect on adjuvant gemcitabine efficacy [76]. This evidence concerns the gene TP53 and neoplasm.